TR201910213T4 - Disülfürle stabilize edilmiş çok değerlikli antikorlar. - Google Patents

Disülfürle stabilize edilmiş çok değerlikli antikorlar. Download PDF

Info

Publication number
TR201910213T4
TR201910213T4 TR2019/10213T TR201910213T TR201910213T4 TR 201910213 T4 TR201910213 T4 TR 201910213T4 TR 2019/10213 T TR2019/10213 T TR 2019/10213T TR 201910213 T TR201910213 T TR 201910213T TR 201910213 T4 TR201910213 T4 TR 201910213T4
Authority
TR
Turkey
Prior art keywords
disulfide
multivalent antibodies
specificity
stabilized
antigen
Prior art date
Application number
TR2019/10213T
Other languages
English (en)
Turkish (tr)
Inventor
Adams Ralph
Hancock Laura
Philip Heywood Sam
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2009/002310 external-priority patent/WO2010035012A1/en
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of TR201910213T4 publication Critical patent/TR201910213T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TR2019/10213T 2009-09-25 2010-09-24 Disülfürle stabilize edilmiş çok değerlikli antikorlar. TR201910213T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB2009/002310 WO2010035012A1 (en) 2008-09-26 2009-09-25 Biological products
GBGB1005063.1A GB201005063D0 (en) 2010-03-25 2010-03-25 Biological products

Publications (1)

Publication Number Publication Date
TR201910213T4 true TR201910213T4 (tr) 2019-07-22

Family

ID=42228366

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10213T TR201910213T4 (tr) 2009-09-25 2010-09-24 Disülfürle stabilize edilmiş çok değerlikli antikorlar.

Country Status (12)

Country Link
US (1) US20120316324A1 (Direct)
EP (1) EP2480577B1 (Direct)
JP (2) JP5931730B2 (Direct)
CN (2) CN102549018B (Direct)
BR (1) BR112012006492A2 (Direct)
CA (1) CA2773286C (Direct)
EA (1) EA201200526A1 (Direct)
ES (1) ES2736649T3 (Direct)
GB (1) GB201005063D0 (Direct)
IN (1) IN2012DN02535A (Direct)
TR (1) TR201910213T4 (Direct)
WO (1) WO2011036460A1 (Direct)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
HRP20170374T1 (hr) 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
WO2011030107A1 (en) * 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB201005064D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
MX2014001883A (es) * 2011-08-17 2014-05-27 Glaxo Group Ltd Proteinas y peptidos modificados.
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
CN103797367B (zh) * 2011-09-06 2016-05-25 马克斯.普朗克促进科学协会 用于分析生物大分子复合物的方法及其用途
PL2776466T3 (pl) 2011-11-11 2018-01-31 Ucb Biopharma Sprl Przeciwciała wiążące albuminę i ich fragmenty wiążące
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
JP2016515093A (ja) 2013-02-05 2016-05-26 サノフイ 抗体−薬物コンジュゲート療法とともに使用するための免疫イメージング剤
US9989524B2 (en) 2013-02-05 2018-06-05 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
PT2953977T (pt) * 2013-02-05 2018-01-29 Sanofi Sa Agente de imunoimagiologia para utilização com uma terapia de conjugado anticorpo-fármaco
ES2644668T3 (es) * 2013-02-05 2017-11-29 Sanofi Agente de formación de inmunoimágenes para el uso con la terapia de conjugado de anticuerpo-fármaco
WO2014124326A1 (en) 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
CA2896359A1 (en) * 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
KR20150122761A (ko) * 2013-02-26 2015-11-02 로슈 글리카트 아게 Ｔ 세포 활성화 항원 결합 분자
JP6422977B2 (ja) * 2013-08-30 2018-11-14 エイプリルバイオ カンパニー リミテッド 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法
EP3065774B1 (en) 2013-11-06 2021-05-26 Janssen Biotech, Inc. Anti-ccl17 antibodies
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
KR20180030917A (ko) 2015-08-05 2018-03-26 얀센 바이오테크 인코포레이티드 항-cd154 항체 및 그의 사용 방법
KR20180087430A (ko) 2015-12-17 2018-08-01 얀센 바이오테크 인코포레이티드 Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
IL304871A (en) * 2016-01-11 2023-10-01 Inhibrx Inc Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
CN107674122A (zh) * 2016-12-28 2018-02-09 天津天锐生物科技有限公司 一种识别人血清白蛋白的单域抗体
ES3015094T3 (en) * 2017-06-05 2025-04-29 Numab Therapeutics AG Anti-hsa antibodies
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
KR102611853B1 (ko) 2017-06-30 2023-12-08 자임워크스 비씨 인코포레이티드 안정화된 키메라 fabs
SG11202004158QA (en) 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
CA3084518A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
CN110551216B (zh) * 2018-05-31 2022-11-18 信达生物制药(苏州)有限公司 多价抗ox40抗体及其用途
TWI806087B (zh) * 2020-06-30 2023-06-21 大陸商和鉑醫藥（上海）有限責任公司 免疫細胞銜接多特異性結合蛋白及其製備和應用
CN115667316A (zh) * 2020-06-30 2023-01-31 和铂医药(上海)有限责任公司 Fab-HCAb结构的结合蛋白
US12297281B2 (en) 2020-08-05 2025-05-13 Synthekine, Inc. IL10RA binding molecules and methods of use
WO2022031884A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rg binding molecules and methods of use
WO2022032025A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr binding synthetic cytokines and methods of use
US11859001B2 (en) 2020-08-05 2024-01-02 Synthekine, Inc. IL12RB1-Binding molecules and methods of use
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines
CN116829585A (zh) 2020-08-05 2023-09-29 辛德凯因股份有限公司 Il27受体结合相关的组合物和方法
MX2023001490A (es) 2020-08-05 2023-04-27 Synthekine Inc Moleculas de union a il27r\03b1 y metodos de uso.
WO2022032023A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il23r binding molecules and methods of use
CN117242088A (zh) 2020-08-05 2023-12-15 辛德凯因股份有限公司 Il10受体结合分子和使用方法
CN117043188A (zh) 2020-08-05 2023-11-10 辛德凯因股份有限公司 Gp130结合分子及使用方法
US12234291B2 (en) 2020-08-05 2025-02-25 Synthekine, Inc. IL2RB binding molecules and methods of use
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
EP4192857A4 (en) 2020-08-05 2025-07-23 Synthekine Inc IL10RB-BINDING MOLECULES AND METHODS OF USE THEREOF
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
WO2022032042A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il12 receptor synthetic cytokines and methods of use
EP4229086A1 (en) 2020-10-15 2023-08-23 UCB Biopharma SRL Binding molecules that multimerise cd45

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
GB9221657D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
DE69531148T2 (de) 1994-01-31 2004-04-29 Trustees Of Boston University, Boston Bibliotheken aus polyklonalen antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE19653722C2 (de) 1996-12-10 2000-06-29 Brose Fahrzeugteile Beidseitig wirkende Verstellvorrichtung
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
WO1998037200A2 (en) 1997-02-21 1998-08-27 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
AU3475100A (en) * 1999-01-29 2000-08-18 Imclone Systems Incorporated Antibodies specific to kdr and uses thereof
ATE422369T1 (de) 1999-12-24 2009-02-15 Genentech Inc Verfahren und zusammensetzungen zur verlängerung der entsorgungshalbwertszeit von biowirksamen verbindungen
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
CA2411374C (en) 2000-06-29 2012-10-30 Abbott Laboratories Dual specificity antibodies and methods of making and using
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
WO2004081026A2 (en) 2003-06-30 2004-09-23 Domantis Limited Polypeptides
AU2003245664A1 (en) 2002-06-21 2004-01-06 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
PT1570267E (pt) 2002-12-03 2012-01-03 Ucb Pharma Sa Ensaio para a identificação de células produtoras de anticorpos
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
SI1644412T2 (sl) 2003-07-01 2018-11-30 Ucb Biopharma Sprl Modificirani fab fragmenti protiteles
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
BRPI0511755A (pt) 2004-06-01 2008-01-02 Domantis Ltd composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
LT2949668T (lt) 2005-05-18 2019-11-11 Ablynx Nv Pagerinti nanokūnai tm prieš navikų nekrozės faktorių alfa
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
CN101448853A (zh) * 2006-03-17 2009-06-03 比奥根艾迪克Ma公司 稳定的多肽组合物
BRPI0709598A8 (pt) * 2006-03-17 2019-01-08 Biogen Idec Inc composições de polipeptídeos estabilizados
EP2535350B1 (en) * 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
HRP20170374T1 (hr) * 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi

Also Published As

Publication number Publication date
WO2011036460A1 (en) 2011-03-31
CA2773286C (en) 2020-10-20
BR112012006492A2 (pt) 2016-11-22
GB201005063D0 (en) 2010-05-12
CN102549018A (zh) 2012-07-04
CN102549018B (zh) 2015-11-25
EP2480577A1 (en) 2012-08-01
CA2773286A1 (en) 2011-03-31
US20120316324A1 (en) 2012-12-13
JP2016106126A (ja) 2016-06-16
JP5931730B2 (ja) 2016-06-08
JP2013505923A (ja) 2013-02-21
EP2480577B1 (en) 2019-04-10
CN105315374A (zh) 2016-02-10
IN2012DN02535A (Direct) 2015-08-28
ES2736649T3 (es) 2020-01-03
EA201200526A1 (ru) 2012-11-30

Similar Documents

Publication Publication Date Title
TR201910213T4 (tr) Disülfürle stabilize edilmiş çok değerlikli antikorlar.
EA201100527A1 (ru) Биологические продукты
PH12021550083A1 (en) Human anti-tau antibodies
CY1123618T1 (el) Πολυπεπτιδια αντισωματα που ανταγωνιζονται cd40l
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
MX357678B (es) Moléculas de unión específica a proteína de unión a adn de respuesta transactiva de 43 kda (tdp-43).
EA201390923A1 (ru) Модифицированное антитело с улучшенным полупериодом существования
MX2024003355A (es) Anticuerpos anti-cd3.
BR112018070823A2 (pt) anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno.
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2
EA201270654A1 (ru) Моноклональные антитела, связывающие b7h6, и их применение
EA201490262A1 (ru) Модифицированные белки и пептиды
MX382398B (es) Proteinas de union a antigeno st2.
BR112014001573B8 (pt) Molécula fv ao antígeno multivalente
MX341921B (es) Proteinas de union a antigeno.
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
CO6382184A2 (es) Proteinas fijadoras de receptores de interleukinas-21
MX2013010571A (es) Ensayo de diagnostico de anticuerpo.
EA200900991A1 (ru) Новые антитела против igf-1r
DE602005022757D1 (de) Verwendung von endosialinbindenden proteinen zum isolieren endosialinpositiver zellen
TH147612A (th) โมเลกุลแอนตี้-gcc แอนตี้บอดี้และองค์ประกอบและวิธีการที่เกี่ยวข้อง
TH148295B (th) เปปไทด์ หรือ สารเชิงซ้อนเปปไทด์ ที่เข้าจับกับ 2 อินทีกริน และ วิธีการและการใช้ที่เกี่ยวข้องกับสิ่งเดียวกันนั้น